Coexistence of Deficiencies of Uroporphyrinogen III Synthase and Decarboxylase in a Patient with Congenital Erythropoietic Porphyria and in His Family by Freesemann, Anne G. et al.
Eur J Clin Chem Clin Biochem 1997; 35(l):35-39 © 1997 by Walter de Gruyter · Berlin · New York
Coexistence of Deficiencies of Uroporphyrinogen III Synthase and
Decarboxylase in a Patient with Congenital Erythropoietic Porphyria
and in His Family
Anne G. Freesemann1, Klaus Hofweber2 and Manfred O. Doss1
1 Abteilung für Klinische Biochemie, Fachbereich Humanmedizin und Klinikum der Philipps-Universität,
Marburg, Germany
2 Kinderkrankenhaus St. Marien, Landshut, Germany
Summary: A hitherto undescribed dual deficiency of uroporphyrinogen III synthase and uroporphyrinogen decarb-
oxylase was observed in the erythrocytes in a 14 year-old patient who had presented with congenital erythropoietic
porphyria since early childhood. Whereas congenital erythropoietic porphyria was metabolically and clinically overt,
a hereditary deficiency of uroporphyrinogen decarboxylase was confirmed by family study. The uroporphyrinogen
III synthase activity of the propositus was decreased to 26% of the control while his asymptomatic family members
had activities between 53-65% of the control. Additionally, the uroporphyrinogen decarboxylase activity was
55—66% of the control in the patient and his family. Family investigations have shown that the two disorders do
not consistently segregate together. Although urinary porphyrin excretions of relatives were in the physiological
range, the proportion of coproporphyrin isomer I showed a relative increase, which can serve as a biochemical
indicator for heterozygous uroporphyrinogen III synthase gene carriers.
Introduction
Porphyrias are mainly hereditary diseases, each one
reflecting a partial genetic defect of one of the en-
zymes in the haem biosynthetic pathway (1). Simulta-
neous presence of the enzyme deficiencies of two
types of hereditary porphyria in one individual and/or
in the same family is characteristic of dual porphyrias.
These conditions are rare, and have so far been
reported only as combinations of acute intermittent
porphyria and porphyria variegata, known as the Ches-
ter Type (McKusick 176010) (2), acute intermittent
porphyria (McKusick 176000) and porphyria cutanea
tarda (McKusick 176100) (3, 4), porphyria variegata
(McKusick 176200) and porphyria cutanea tarda
(5—8), and hereditary coproporphyria (McKusick
121300) with congenital erythropoietic porphyria
(McKusick 163700) (9) (fig. 1).
This present report describes a patient with congenital
erythropoietic porphyria who was also found to have
coincidentally inherited half-normal activity of uro-
porphyrinogen decarboxylase1).
Patient and Methods
The male patient, born in 1981, developed excessive haemolytic
anaemia as a newborn. Photosensitivity became obvious after pho-
totherapy which was indicated because of severe jaundice. Blister-
ing occurred on foot, stomach, chest and forehead, and the healed
areas were hypopigmented. Additionally, red coloured urine was
observed. Family members were clinically unaffected. During the
subsequent years the clinical symptoms of congenital erythropoi-
etic porphyria seen in the patient exacerbated and were accompa-
nied by development of severe osteoporosis, renal and liver sidero-
sis and nephrotic syndrome (10). Further porphyrin studies were
performed in 1995.
Porphyrins were determined by high performance thin-layer
chromatography in combination with absorption spectrophotome-
try (11). Urinary and faecal coproporphyrin isomers I/III were
analysed as free acids by C8 reversed phase high performance
liquid chromatography in connection with fluorometric detection
(12). Porphobilinogen synthase, porphobilinogen deaminase and
uroporphyrinogen decarboxylase activities were determined as
previously described (3, 14, 15). Uroporphyrinogen III synthase
activity in red cell lysates was determined by a coupled enzyme
assay adapted from Tsai et al. (16) with slight modifications.
Incubation was carried out at 37 °C for 15 min in the dark. The
reaction was stopped by the addition of 500 trichloroacetic
acid containing iodine and riboflavin. The latter served as an
internal standard. The oxidized uroporphyrin isomers were sepa-
rated by G« reversed-phase HPLC (RP 18 LiChroCART® 4 · 70
mm, Merck, Darmstadt, Germany) and quantitated by fluoromet-
ric detection.
') Enzymes
Porphobilinogen synthase (EC 4.2.1.24)
Porphobilinogen deaminase (EC 4.3.1.8)
Uroporphyrinogen III synthase (EC 4.2.1.75)
Uroporphyrinogen decarboxylase (EC 4.1.1.37)
Results
The first pathobiochemical investigation of the patient
at the age of 24 days showed elevated porphyrin levels
in urine, faeces and blood. Metabolic data are compiled
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Fig. 1 All the known dual porphyrias and the corresponding defective enzymes in haem biosynthesis
(* indicates the dual enzyme deficiency reported in this paper).
in table 1 and 2. Urinary porphyrins consisted mostly of
uro- and coproporphyrins, while the predominant faecal
porphyrin was coproporphyrin; in each case there was
a high predominance of isomer I. These characteristic
constellations confirmed the clinical suspicion of con-
genital erythropoietic prophyria. We found a decreased
activity of uroprophyrinogen decarboxylase in erythro-
cytes, which is not typical of congenital erythropoietic
porphyria. We therefore performed metabolic and en-
zyme studies on both the patient and his parents. Por-
phyrinaemia and porphyrinuria were exacerbated with
clear predominance of uroprophyrin in urine and blood.
Enzyme studies again showed a reduced activity of uro-
porphyrinogen decarboxylase (60% of control) and re-
vealed a dual deficiency with decreased activity of both
uroporphyrinogen III synthase (26% of control), as seen
in congenital erythropoietic porphyria, and uroporphyri-
nogen decarboxylase, as seen in porphyria cutanea
tarda (tab. 3).
His parents had decreased uroporphyrinogen III syn-
thase activities at an intermediate level (around 60% of
control) and, notably, both parents also showed de-
creased activity of uroporphyrinogen decarboxylase
(tab. 3), i. e. both parents were double heterozygotes
(fig. 2). Red cell porphobilinogen synthase and deami-
nase activities were normal in the patient and his family
(data not shown). No significant increases in porphyrins
were found in urine, faeces or blood of family members.
However, the urinary coproporphyrins of family mem-
bers showed an increase in the isomeric series I (tab. 1).
His sister was also found to be doubly heterozygous for
the trait of congenital erythropoietic porphyria and por-
phyria cutanea tarda, as shown by enzyme activities and
a slight increase in the proportion of urinary copropor-
phyrin I (tabs. 1 and 3).
Discussion
A male child with a hitherto undescribed double enzyme
deficiency of uroporphyrinogen III synthase and uro-
porphyrinogen III decarboxylase, associated with the
clinical feature of congenital erythropoietic porphyria, is
presented. His parents were found to be heterozygous
for both the trait of congenital erythropoietic porphyria
and the trait of porphyria cutanea tarda. Therefore, the
Fig. 2 Pedigree of family with dual enzyme deficiency.
€ B heterozygous deficient of uroporphyrinogen III synthase
and uroporphyrinogen decarboxylase activities, M heterozygous
deficient of uroporphyrinogen decarboxylase activity and homo-
zygous deficient of uroporphyrinogen III synthase activity,
• clinical manifestation of congenital erythropoietic porphyria;
/* propositus.
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uroporphyrinogen decarboxylase deficiency of the pa-
tient was inherited. Low erythrocyte uroporphyrinogen
decarboxylase activity is observed in porphyria cutanea
tarda type II, the familiar type (1, 17). The genes encod-
ing uroporphyrinogen III synthase and uroporphyrino-
gen III decarboxylase are located on different chromo-
somes. The human congenital erythropoietic porphyria
gene has been mapped to chromosome 10 q25 · 2
— q26 - 3 (18—21). The gene for uroporphyrinogen de-
carboxylase has been assigned to the region 1 pter-p34
of the human chromosome 1 (17). This suggests that this
case of dual enzyme deficiency results from the inciden-
tal genetic transmission of two independently occurring
gene defects, as confirmed by the family investigation
(tab. 3). The patient received a uroporphyrinogen III
synthase gene defect from each parent and a uroporph-
yrinogen decarboxylase gene defect from only one par-
ent (fig. 2). From this it can be concluded that these two
defects do not segregate together. Hepatoerythropoietic
porphyria, the homozygote form of porphyria cutanea
tarda, can be excluded by the enzymatic and metabolic
data given before.
The propositus developed the clinical syndrome of con-
genital erythropoietic porphyria shortly after birth. Co-
inheritance of uroporphyrinogen decarboxylase defi-
ciency does not appear to have modified the phenotype
of congenital erythropoietic porphyria. Whereas congen-
ital erythropoietic porphyria follows an autosomal reces-
sive trait of inheritance, genetically determined por-
phyria cutanea tarda follows an autosomal dominant trait
of inheritance, though with a low clinical penetrance.
Lack of modification of the phenotype by uroporphyri-
nogen decarboxylase deficiency is not unexpected, since
in most of those known to have inherited this deficiency
it is clinically and metabolically latent (17). Furthermore
congenital erythropoietic porphyria and porphyria cuta-
nea tarda are both porphyrin accumulation disorders in
which skin photosensitivity and chronic photodermato-
sis are main clinical symptoms (22, 23). Cutaneous
symptoms of congenital erythropoietic porphyria are
much more severe than those of porphyria cutanea tarda;
in addition, porphyria cutanea tarda usually becomes
clinically overt in adult life (1, 24). Therefore, the clin-
ical consequences of the uroporphyrinogen decarboxyl-
ase gene defect would be covered by the clinical features
of congenital erythropoietic porphyria.
The porphyrin metabolite pattern of the patient reflected
uroporphyrinogen III synthase deficiency. A slight meta-
bolic expression of uroporphyrinogen decarboxylase de-
ficiency became obvious from the higher proportion
(1 : 0.3) of urinary uroporphyrin, in comparison with
other congenital erythropoietic porphyria cases (1 : 0.6;
n = 7). Additionally, reinvestigation after 14 years re-
vealed an increase in the proportion of uroporphyrin
from 47% to 68% of total urinary porphyrins.
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Tab. 2 Blood porphyrin profiles of the family
































































Tab. 3 Enzyme activities in the erythrocytes of the patient and his relatives (cf. pedigree in fig. 2)



























[x ± SD (n)]
22 ± 3 (68)
702 ± 62 (10)
2.8 ± 0.4 (35)
The uroporphyrinogen III synthase deficiency is clini-
cally overt in the homozygous state, but clinically silent
in the heterozygous condition. Total porphyrin excretion
as well as urinary uro- and coproporphyrin excretion of
the gene carriers (parents and sister) were normal. How-
ever, the relative increase of coproporphyrin isomer I
indicates intermediate uroporphyrinogen III synthase de-
ficiency. This isomer III/I inversion is a metabolically
intriguing sign and can serve as a biochemical indicator
of heterozygotes. Uroporphyrinogen decarboxylase defi-
ciency is clinically silent in family members. Urinary
uro- and heptacarboxyporphyrin excretion are normal,
indicating that, at the time of investigation, the disposi-
tion for porphyria cutanea tarda was in the genetic phase
without metabolic consequences (22). All types of por-
phyria cutanea tarda can be triggered by liver diseases,
alcohol and oestrogens (1). Obviously, the parents were
not exposed to such triggering factors. The observation
that a porphyria cutanea tarda gene carrier can show a
decreased enzyme activity without metabolic and clin-
ical consequences is well known (17, 25).
This combination of congenital erythropoietic porphyria
and hereditary coproporphyria (9), is also the second
report of a dual enzyme deficiency in which one disor-
der is autosomal recessive and the other is autosomal do-
minant.
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